Press Release: Catamaran Bio : Catamaran Bio Presents Preclinical Efficacy Data for Two Allogeneic CAR-NK Cell Therapies for Solid Tumors at SITC 2022 Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Catamaran Bio, Inc., a biotechnology company developing off-the-shelf NK cell therapies to treat cancer, today announced new data demonstrating preclinical efficacy of two CAR-NK cell therapies in solid and hematological cancers. The data are being presented in two posters at the Society for Immunotherapy in Cancer (SITC) 37th Annual Meeting, being held in Boston, Massachusetts, November 8-12, 2022. "Collectively, these preclinical data sets demonstrate the po